Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
about
Immunotherapy of systemic sclerosisRituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-AnalysisSalivary Secretory Disorders, Inducing Drugs, and Clinical ManagementCellular targeting in autoimmunitySjögren's syndrome: still not fully understood diseaseUnderstanding the role of B cells in atherosclerosis: potential clinical implicationsSF-36 total score as a single measure of health-related quality of life: Scoping reviewMultiple Roles for B-Lymphocytes in Sjogren's SyndromeFatigue in rheumatic diseasesInterleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trialTreatment of primary Sjögren syndrome.B cells and atherosclerosis.Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.Text-mining applied to autoimmune disease research: the Sjögren's syndrome knowledge base.[Current "off label use" of methotrexate for chronic inflammatory rheumatic diseases].Rituximab in primary Sjögren's syndrome: a ten-year journey.Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data.Novel aspects of Sjögren's syndrome in 2012.Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome.Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-InteRates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.Protein-Losing Gastroenteropathy Associated With Sjögren's Syndrome: First Known Case Reported Outside of Asia.B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance TreatmentWhich and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED).A five-year prospective study of fatigue in primary Sjögren's syndrome.TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndromeSignificance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.Advances in human B cell phenotypic profiling.Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome.[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjogren's syndromePharmacotherapy of scleritis: current paradigms and future directions.Immunomodulatory drugs: oral and systemic adverse effects.Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept
P2860
Q24634395-9C3B354A-F405-41EC-B545-D0A42DEA6B29Q26753072-98EBE7F0-668D-4CC8-A865-AAF9445DABF7Q26777907-1F33CD44-C444-48DB-8EB0-AAE300DD97EEQ26824580-41869076-6A2E-4890-A51A-4352F4509090Q26851943-9449EEBA-F396-44BA-886C-E4EB1E22CB75Q26991813-A9225956-E598-4C5C-B9EC-5E9B7C8386D4Q28066146-04C2B8F7-D399-4CE9-B663-010AE15E2FBAQ28068695-5F77B330-380D-46B8-8EEA-AF046E9B9921Q28079588-5EC1EE04-7184-47DE-8D0D-D669CC4E2C36Q28478765-9983799A-6CA2-43D1-BA4B-B7197A7C0EEFQ30249011-ABF88C0B-9549-4145-AD0C-F60DB29488C6Q30252928-1C3B9FFD-A05E-4E64-9AAD-1AB5C138AEEAQ30948155-03FA5924-EBDC-404A-BC10-EC695C32F2A9Q31070967-7DA22425-CFDC-403C-A327-09267197DBDCQ34160848-A7879DC6-9BBC-41AB-98B9-ADF8EC31AECDQ34432465-1DBC05CB-FD84-4AC1-A8DB-B6AAA24F4ABAQ34495053-C0AF2893-CA61-4098-B0D9-03A077D58855Q34650103-0149916B-1D70-43CD-9AB6-9583011A9AEAQ34984739-40E9EF3B-356D-4272-866A-EC33DE7D4E18Q35196207-9EE8EEAB-3921-4D95-A19C-8B25CA9C21AEQ35318424-111ACFC0-9DD1-406A-95D3-697FB8C8F7B1Q35617617-91B1175B-E94A-40CF-BBFB-F8A4C314852BQ35618308-DD05F473-6642-4936-B4DC-32D9FDD2A1ADQ35680023-8B9C48C4-467D-4544-BC6F-C3101A26D928Q35774612-93951D2E-E202-4A98-BB45-5C40FA921A8CQ35805082-091AB1FA-8DA1-4C17-987D-5135EA01B6D6Q35840801-6C3209AA-B299-426F-A8AC-0EB9C3550089Q35857131-D3B0CA73-FB1E-4CEC-A8EB-A283D7B99CB8Q35907701-F61D704C-0A5A-41AE-93C3-88DFFB743986Q36060629-8610F18B-32C7-4550-8C41-67509F88F62AQ36214855-A23A0A84-4E32-4513-8403-7E7E3DEA7BCBQ36307080-6B15C80F-B761-41C1-B7C2-30EEFA4AF057Q36318183-320B0ED3-D8CC-4BD1-92CE-43330BD2AA14Q36394613-DE7EA89F-0D5C-4EA7-8C6E-F070AECFFAC9Q36745666-89A0B7A3-205B-4AC0-9D9C-039B749BCA5FQ37044113-2E00C8C7-102E-4FA5-A934-EBBE99884A03Q37466204-60C09854-4B91-4DBF-853B-C6EAE4403B78Q37539743-851FF459-7680-4191-A274-B89E1F8A40BAQ37691074-DA024429-ABE9-48E2-BFD8-0C145A40F7CDQ37696041-55B046B9-1055-4F9C-BC6A-95BCD6989B4A
P2860
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@en
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@nl
type
label
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@en
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@nl
prefLabel
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@en
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@nl
P2093
P356
P1476
Effectiveness of rituximab tre ...... ind, placebo-controlled trial.
@en
P2093
C G M Kallenberg
F K L Spijkervet
J M Meijer
N Kamminga
P M Meiners
W Abdulahad
P304
P356
10.1002/ART.27314
P577
2010-04-01T00:00:00Z